We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Certest Offers Real-Time PCR Assays for Fast Detection of MDR Bacterial Infections

By LabMedica International staff writers
Posted on 23 Sep 2021
Print article

CerTest Biotec (Zaragoza, Spain) has joined the fight against multidrug resistant strains (MDR) bacterial infections by developing real-time PCR assays for the fast detection of genes or punctual mutations that confer resistance to antibiotics from both Gram-positive and Gram-negative pathogens.

Resistance to antibiotics is a natural phenomenon, through which bacteria are able to adapt and survive the activity of these compounds and poses a serious global threat of growing concern to human, animal, and environment health. This is due to the emergence, spread, and persistence of the “superbugs.” Multidrug bacteria exist across the animal, human, and environment triangle and there is interlinked sharing of these pathogens in this triad. The plausible causes of the AMR include excessive use of antibiotics in animals and humans, antibiotics sold over-the-counter, poor sanitation, and release of non-metabolized antibiotics or their residues into the environment through manure. These factors contribute to genetic selection pressure for the emergence of MDR bacterial infections in the community.

Initial inappropriate antimicrobial therapy of severe infections leads to an increased morbidity and mortality. Adequate therapy of severe infections caused by MDR is challenging as many of the main compounds typically used for infections caused by susceptible microorganisms are inactive. This may lead to extensive use of broad-spectrum antibiotics, which would contribute to selection of further resistance and may also expose patients to unnecessary toxicity.

Routine antibiogram techniques are based on a phenotypic study in which microbial growth is observed in the presence of different antibiotics. These techniques include broth macrodilution and microdilution (the gold standard for the antibiogram), agar dilution and strips with an antibiotic gradient. They yield results in around 17 hours. This is why alternative techniques to conventional diagnosis are required that present greater speed, sensitivity, specificity and ability to detect microorganisms, along with their antibiotic resistance mechanism. In addition, techniques are sought with the highest degree of automation possible, ease of implementation and a good cost effectiveness ratio.

CerTest has developed real-time PCR assays for the fast detection of genes or punctual mutations that confer resistance to antibiotics from both Gram-positive and Gram-negative pathogens. These products include multiplex assays for the detection of the principal carbapenem-resistance genes, Methicillin-resistant Staphylococcus aureus infections (MRSA), vancomycin-resistant enterococci (VRE), and the principal beta-lactamase genes. These four multiplex assays cover the main antibiotic resistance genes associated with MDR bacterial infections and sepsis-causing pathogens.

The advantage of these multiplex products is that they can each be used individually or as a broad-spectrum panel to evaluate a sample from a patient. They have been validated both in swab specimens and direct-from-blood. This clinical diagnostic tool allows obtaining the results without having to wait for the incubation time of a culture and has proven to be more sensitive and accurate than these traditional techniques, being able to initiate a personalized treatment, offering a structural model for efficient health care and avoiding the massive use of antibiotics.

Related Links:

CerTest Biotec

Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
Handheld β-Ketone and Glucose Analyzer
STAT-Site WB Analyzer
Molecular Diagnostic Platform
Silver Supplier
Bench-Top Molecular Microarray System
NanoCHIP XL Analyzer

Print article



view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more


view channel

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more


view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more


view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.